Dajun Yang, MD, PhDChairman and CEO at Ascentage Pharma
Dr. Dajun Yang is the Chairman and CEO of Ascentage Pharma. Dr. Yang has dedicated his career to the research on apoptosis and innovative drug R&D for nearly 30 years. In 2009, he co-founded Ascentage Pharma and made major breakthroughs in the research of development of precision drugs targeting apoptosis and autophagy dual-channel regulation. Ascentage Pharma is the only company in the world that researches and develops innovative drugs targeting all these pathways. Ascentage Pharma currently has eight potential “First-in-class” or “Best-in-class” innovative drug candidates in Phase I/II clinical developments in China, the United States and Australia. Dr. Yang has undertaken nearly ten National Science and Technology Major Projects such as the National High-tech R&D Program (the “863 Program”) and the Major Innovative Drug Developments program. The teams led by Dr. Yang has won multiple awards such as the Major Innovation Team of Suzhou and Jiangsu, the First Jiangsu Innovation Competition Team Award, and the R&D Achievement of the Year 2017 from the BayHelix Group. Dr. Yang is the recipient of the 2018 “Dushu Lake Prize” for the Most Influential Leader in Drug R&D, awarded in recognition of his exceptional contribution to the field. Dr. Yang was the president of Chinese Biopharmaceutical Association-USA from 2005 to 2006 and has concurrently served as professor and Ph.D. supervisor at Sun Yat-sen University Cancer Center, director of the Drug R&D Specialty Committee of China Pharmaceutical Innovation and Research Development Association, and assistant researcher in Pharmaceutical Innovations at Shanghai Institute of Materia Medica, Chinese Academy of Sciences.